Cargando…

Discovery of a Phosphodiesterase 9A Inhibitor as a Potential Hypoglycemic Agent

[Image: see text] Phosphodiesterase 9 (PDE9) inhibitors have been studied as potential therapeutics for treatment of diabetes and Alzheimer’s disease. Here we report a potent PDE9 inhibitor 3r that has an IC(50) of 0.6 nM and >150-fold selectivity over other PDEs. The HepG2 cell-based assay shows...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shao, Yong-xian, Huang, Manna, Cui, Wenjun, Feng, Ling-Jun, Wu, Yinuo, Cai, Yinghong, Li, Zhe, Zhu, Xinhai, Liu, Peiqing, Wan, Yiqian, Ke, Hengming, Luo, Hai-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2014
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281101/ https://www.ncbi.nlm.nih.gov/pubmed/25432025 http://dx.doi.org/10.1021/jm500836h

Ejemplares similares

Dual Specificity and Novel Structural Folding of Yeast Phosphodiesterase-1 for Hydrolysis of Second Messengers Cyclic Adenosine and Guanosine 3′,5′-Monophosphate
por: Tian, Yuanyuan, et al.
Publicado: (2014)

Structural Asymmetry of Phosphodiesterase-9, Potential Protonation of a Glutamic Acid, and Role of the Invariant Glutamine
por: Hou, Jing, et al.
Publicado: (2011)

Discovery of the First in Class 9-N-Berberine Derivative as Hypoglycemic Agent with Extra-Strong Action
por: Khvostov, Mikhail V., et al.
Publicado: (2021)

Discovery of highly selective and orally available benzimidazole-based phosphodiesterase 10 inhibitors with improved solubility and pharmacokinetic properties for treatment of pulmonary arterial hypertension
por: Yang, Yuncong, et al.
Publicado: (2020)

Adherence to Oral Hypoglycemic Agents in Hawaii
por: Lee, Rachel, et al.
Publicado: (2005)

New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
por: Ni, Xiayun, et al.
Publicado: (2022)

Hypoglycemic agents and potential anti-inflammatory activity
por: Kothari, Vishal, et al.
Publicado: (2016)

An arch-bridge-type fluorophore for bridging the gap between aggregation-caused quenching (ACQ) and aggregation-induced emission (AIE)
por: Huang, Manna, et al.
Publicado: (2016)

Virtual Screening-Accelerated Discovery of a Phosphodiesterase 9 Inhibitor with Neuroprotective Effects in the Kainate Toxicity In Vitro Model
por: Landucci, Elisa, et al.
Publicado: (2023)

The Management of Type 2 Diabetic Patients with Hypoglycemic Agents
por: Carnevale Schianca, G. P., et al.
Publicado: (2012)

Oral hypoglycemic agents: do the ends justify the means?
por: Langer, Oded
Publicado: (2015)

Utility of Hypoglycemic Agents to Treat Asthma with Comorbid Obesity
por: Ge, Derek, et al.
Publicado: (2022)

Discovery of novel phosphodiesterase-1 inhibitors for curing vascular dementia: Suppression of neuroinflammation by blocking NF-κB transcription regulation and activating cAMP/CREB axis
por: Zhou, Qian, et al.
Publicado: (2023)

Discovery of catalytic-site-fluorescent probes for tracing phosphodiesterase 5 in living cells
por: Qiu, Meiying, et al.
Publicado: (2021)

Discovery of novel PDE9A inhibitors with antioxidant activities for treatment of Alzheimer’s disease
por: Zhang, Chen, et al.
Publicado: (2017)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No
por: Kassem, Sameer A., et al.
Publicado: (2009)

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?
por: Górriz, Jose Luis, et al.
Publicado: (2015)

Bioactives of Momordica charantia as Potential Anti-Diabetic/Hypoglycemic Agents
por: Xu, Bilin, et al.
Publicado: (2022)

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases
por: Park, Sung-Jun, et al.
Publicado: (2012)

Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis
por: Xin, Wen-Xiu, et al.
Publicado: (2018)

Lychee Seed as a Potential Hypoglycemic Agent, and Exploration of its Underlying Mechanisms
por: Zhang, Yuehong, et al.
Publicado: (2021)

Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis
por: Zhao, Zimo, et al.
Publicado: (2023)

Discovery of lixisenatide analogues as long-acting hypoglycemic agents using novel peptide half-life extension technology based on mycophenolic acid
por: Tang, Chunli, et al.
Publicado: (2020)

Study of Hypoglycemic Activity of Novel 9-N-alkyltetrahydroberberine Derivatives
por: Khvostov, Mikhail V., et al.
Publicado: (2022)

Evaluation of mulberry leaves’ hypoglycemic properties and hypoglycemic mechanisms
por: Chen, Sikai, et al.
Publicado: (2023)

Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity/Mortality? Yes
por: Bianchi, Cristina, et al.
Publicado: (2009)

Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
por: Dawed, Adem Yesuf, et al.
Publicado: (2016)

Cognition and drug adherence to oral hypoglycemic and antihypertensive agents in older adults
por: Bakouni, Hamzah, et al.
Publicado: (2019)

Meta-analysis of the association between new hypoglycemic agents and digestive diseases
por: Wang, Yu-Wen, et al.
Publicado: (2022)

Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease
por: Su, Tao, et al.
Publicado: (2016)

Adherence to Hypoglycemic Agents in Type 2 Diabetes Mellitus: A Cross-Sectional Study
por: Khayyat, Yara A, et al.
Publicado: (2022)

9-N-n-alkyl Berberine Derivatives: Hypoglycemic Activity Evaluation
por: Khvostov, Mikhail V., et al.
Publicado: (2022)

Hypoglycemic unawareness: challenges, triggers, and recommendations in patients with hypoglycemic unawareness: a case report
por: Sharifi, Yasaman, et al.
Publicado: (2022)

Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation
por: TAJIMA, Tsuyoshi, et al.
Publicado: (2018)

Latent autoimmune diabetes of adults: From oral hypoglycemic agents to early insulin
por: Poudel, Resham R.
Publicado: (2012)

Drug-drug interaction between voriconazole and oral hypoglycemic agents in diabetic rats
por: Kumar, Boyina Hemanth, et al.
Publicado: (2013)

Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
por: Moon, Min Kyong, et al.
Publicado: (2017)

Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
por: Moon, Min Kyong, et al.
Publicado: (2017)

Cognition and drug adherence to oral hypoglycemic and antihypertensive agents in older adults [Corrigendum]
Publicado: (2019)

New hypoglycemic agents and the kidney: what do the major trials tell us?
por: Smyth, Brendan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bu6sv7tr9n3mlqi84gsbhsrcpf